Read the following argument and evaluate the statement below it.
Argument: A pharmaceutical company can receive expedited regulatory approval for a new drug only if the drug treats a life-threatening condition and demonstrates significant clinical improvement over existing therapies. Vaxica's new drug demonstrates significant clinical improvement over existing therapies, yet the regulatory board denied it expedited approval. Therefore, Vaxica's new drug must not treat a life-threatening condition.
Statement: The argument's reasoning relies on assuming that treating a life-threatening condition and demonstrating significant clinical improvement over existing therapies are sufficient conditions for receiving expedited regulatory approval.
Answer: Answer